The estimated Net Worth of Matthew Ferguson is at least $84.3 Thousand dollars as of 8 March 2023. Mr Ferguson owns over 1,287 units of Aziyo Biologics stock worth over $69,291 and over the last 10 years he sold AZYO stock worth over $15,002.
Mr has made over 8 trades of the Aziyo Biologics stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 1,287 units of AZYO stock worth $1,918 on 8 March 2023.
The largest trade he's ever made was buying 28,000 units of Aziyo Biologics stock on 2 December 2022 worth over $126,280. On average, Mr trades about 3,134 units every 164 days since 2015. As of 8 March 2023 he still owns at least 46,504 units of Aziyo Biologics stock.
You can see the complete history of Mr Ferguson stock trades at the bottom of the page.
Matthew B. Ferguson is the Chief Financial Officer at Aziyo Biologics.
Mr Ferguson is 53, he's been the Chief Financial Officer of Aziyo Biologics since . There are 5 older and 1 younger executives at Aziyo Biologics. The oldest executive at Aziyo Biologics, Inc. is Dr. Jerome Riebman FACC, M.A., M.D., 67, who is the Chief Medical Officer.
Matthew's mailing address filed with the SEC is C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING, MD, 20904.
Over the last 4 years, insiders at Aziyo Biologics have traded over $0 worth of Aziyo Biologics stock and bought 1,874,715 units worth $13,645,959 . The most active insiders traders include Capital, L.P.Highcape Partn..., Capital, Lp Birchview Fund ..., and C Randal Mills. On average, Aziyo Biologics executives and independent directors trade stock every 41 days with the average trade being worth of $124,230. The most recent stock trade was executed by C Randal Mills on 21 June 2023, trading 22,474 units of AZYO stock currently worth $33,486.
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Aziyo Biologics executives and other stock owners filed with the SEC include: